hCG on TRT:
What Does “Keeping the Testes Working” Actually Mean?

Serum testosterone is the testosterone measured in blood. Intratesticular testosterone is the local concentration within the testes. The latter normally greatly exceeds the former. In Roth’s suppression experiment, replacing circulating testosterone with gel did not reproduce the testicular hormonal environment created by gonadotropin stimulation.^[2]

Think of the blood result as a reading from one location, not an inventory of every tissue. A satisfactory number can coexist with an unmet reproductive goal. Conversely, an unusual hormone value is not enough to explain every sexual symptom. The measurement and the question must match.

This distinction is also why “my testosterone is high, so fertility should be fine” is the wrong inference. A hormone concentration is not a count of viable sperm, and neither is a direct observation of a pregnancy. Even an excellent mechanistic experiment only answers the question its design actually tested.

Normally, hypothalamic GnRH stimulates pituitary LH and FSH. LH acts on Leydig cells to support testosterone production; FSH acts through Sertoli cells to support sperm development. External testosterone feeds back on the system and can suppress both gonadotropins. hCG acts at the LH/hCG receptor, providing stimulation downstream of that suppression.^[7][12]

Calling this “restarting natural production” needs qualification. Production within the testes can be stimulated, but it remains pharmacologically driven. A bypass is different from recovery of the upstream feedback system. It is therefore possible for a treatment to work at its target while the original pituitary signal remains low.

The distinction also explains why hCG, FSH and a SERM are not interchangeable fertility tools. One stimulates a gonadal receptor, another supplies a different gonadotropin, and a SERM attempts to change central feedback. Their suitability depends on the underlying diagnosis. Our enclomiphene versus testosterone guide explores the restoration-versus-replacement comparison.

Coviello and colleagues randomized 29 healthy men to testosterone enanthate, 200 mg intramuscularly weekly, plus placebo or subcutaneous hCG every other day for three weeks. The hCG arms used 125, 250 or 500 IU. These were experimental suppression conditions, not a validated personal TRT protocol. Twenty-seven men had paired intratesticular measurements.^[1]

The placebo arm lost 94% of its baseline intratesticular testosterone. hCG produced a dose-responsive preservation signal. LH and FSH nevertheless remained profoundly suppressed. Semen outcomes were not the study endpoint: three weeks could establish a hormonal effect, not durable fertility.^[1]

A separate 10-day experiment in 37 men used a GnRH antagonist to suppress gonadotropins, then compared very low hCG exposures with placebo or testosterone gel. It likewise investigated local androgen responses, not pregnancies. That independent experimental approach strengthens the mechanistic story without completing the clinical one.^[2]

A promising small TRT series

Hsieh’s retrospective series included 26 men receiving injectable testosterone or gel plus intramuscular hCG, 500 IU every other day. Mean follow-up was 6.2 months, with some longer observations. No participant became azoospermic; nine contributed to a partner pregnancy. There was no randomized TRT-only control.^[3]

Those are encouraging observations, not a guaranteed protection rate. Nine pregnancies among 26 participants cannot be read as the probability of conception for a couple: the number actively trying, opportunity to conceive and partner factors matter. Nor should pregnancy be silently relabeled as live birth. The accessible report does not establish a comparative live-birth benefit.

Newer evidence adds signals, not certainty

A 2025 retrospective report studied 19 men continuing non-prescribed androgens. Over three to six months of hCG treatment, abstract-reported mean total sperm count rose from 18.0 to 146.9 million and total motile sperm count from 1.1 to 66.9 million. Some men remained oligospermic or azoospermic. Without randomization, these within-person changes do not isolate hCG from other changes or establish safety of continued androgen exposure.^[4]

Stocks and colleagues examined 77 men with prior testosterone use receiving hCG plus FSH; 74% improved sperm concentration. Fifty were not using concurrent testosterone and 27 were. This was a retrospective combination-treatment cohort, not a randomized demonstration that continuing TRT is equivalent to stopping it, and not evidence for hCG alone.^[6]

The 2026 open-label trial is particularly instructive. It enrolled men with congenital hypogonadotropic hypogonadism, not a typical established-TRT population. Treatment groups included hCG plus FSH with or without testosterone, or sequential hCG then combination treatment. Sperm-production rates and time to spermatogenesis did not differ significantly between groups. Seven of 45 randomized participants were lost to follow-up. A nonsignificant difference in a small trial is not proof of universal equivalence.^[7]

Recovery after stopping is a separate problem

In Kohn’s cohort, testosterone was stopped and hCG/SERM therapy begun. Forty-six of 66 men reached a total motile sperm count above five million within 12 months. Older age and longer prior testosterone exposure were associated with slower recovery. That threshold was an analytic endpoint—not a promise of natural conception, and not evidence that everyone recovers on the same timetable.^[5]

The 2024 AUA/ASRM guideline cautions against exogenous testosterone when near-term family building is intended. It acknowledges preservation reports involving adjunctive treatments but considers that literature too limited to recommend the approach routinely. Later observational reports are relevant updates, not a reason to erase the difference between a plausible option and a dependable fertility plan.^[11]

Testicular size is a legitimate concern, but it is not a visual fertility test. Long-term hCG treatment in a small series of men with isolated hypogonadotropic hypogonadism was associated with testicular growth and sperm production. That disease-treatment setting cannot supply a universal estimate for size preservation in men already receiving TRT.^[9]

There is a useful counterexample to the slogan that stimulation always makes testes larger. In a placebo-controlled trial of 40 older men with partial androgen deficiency, three months of recombinant hCG increased testosterone and lean mass, but testicular volume decreased; strength and physical function did not significantly improve. This was hCG monotherapy, not low-dose adjunctive TRT treatment. The appropriate lesson is that population, formulation and endpoint matter—not that one study predicts every user’s experience.^[8]

A person’s reported improvement should not be dismissed merely because it is subjective. The mistake is assigning a precise mechanism before testing it. Better libido might be the observation; “brain neurosteroids were restored” is an explanation that needs additional evidence. Those two statements deserve different confidence levels.

For the same reason, adding a second treatment after an unsatisfactory response should not make the original goal disappear. If the goal is comfortable sexual function, ask about sexual function. If it is conception, assess reproductive outcomes. An attractive laboratory trend can otherwise become a substitute for the result that prompted treatment.

The testes produce steroid intermediates as well as testosterone. In a human suppression experiment involving 23 men, hCG stimulated intratesticular androstenedione and DHEA after gonadotropin withdrawal. Circulating DHEA, however, did not mirror the suppression inside the testes. This directly illustrates why one compartment cannot stand in for another.^[10]

We did not identify a randomized TRT-add-on trial demonstrating that hCG improves well-being by restoring brain neurosteroids. That is a bounded finding from this search, not proof that no future benefit is possible. It is also not a reason to rebrand every improvement or adverse experience as a neurosteroid effect.

A convincing test would keep the background treatment stable, compare hCG with an appropriate control, prespecify patient-reported outcomes and measure candidate mediators. Otherwise, a change in symptoms and a plausible pathway can travel together without establishing causation. Mechanistic enthusiasm is most useful when it produces a testable prediction.

The US Pregnyl label includes selected cases of male hypogonadotropic hypogonadism. It does not provide a blanket indication for every man on TRT or for neurosteroid optimization. Male-relevant concerns include gynecomastia, fluid retention and injection reactions; hypersensitivity, including anaphylaxis, is reported. The label requires caution with several conditions, including cardiac or renal disease, and lists male breast or prostate tumors among contraindications.^[12]

Product and route matter: the referenced US product is labeled for intramuscular administration, while some research used subcutaneous exposure. A study’s route and schedule should not be silently turned into universal instructions. The combination also needs assessment as a combination: adding testicular stimulation can change the hormonal exposure produced by a previously stable regimen.

For a clinician discussion, the high-value questions are concrete:

• What is the goal? Size, symptoms, preserving options or attempting pregnancy soon?
• What was the baseline? Prior fertility and semen results matter more than assumptions based on appearance.
• What diagnosis is being treated? A missing signal and primary testicular failure are not the same problem.
• What would count as success? Choose an endpoint and a review interval before interpreting an anecdotal response.
• What happens if it does not work? A fertility specialist can discuss further evaluation, sperm preservation and treatment alternatives.

This is a framework for asking better questions, not a self-managed treatment algorithm. If family building matters, raise it before assuming that an add-on has protected it. A plan that measures the desired outcome is stronger than reassurance based on a hormone result alone.^[11]

hCG’s appeal has a real biological foundation: a testicular signal lost during testosterone-induced suppression can be supplied downstream. The uncertainty is not whether the mechanism exists, but how reliably it delivers each desired clinical outcome in a particular setting.

The fairest summary is specific: strong mechanistic support for local testosterone stimulation; promising but limited clinical evidence for sperm preservation or recovery; context-dependent size findings; and an unproven neurosteroid explanation for added well-being. Neither enthusiasm nor caution improves the evidence by combining those claims into one.

“Keeping the testes working” is therefore the beginning of the conversation, not the conclusion. Ask which function, measured how, in which population, and with what uncertainty. That is how a compelling mechanism becomes a useful decision rather than an oversized promise.